GlaxoSmithKline Plc agreed to pay about $460 million to resolve a majority of lawsuits alleging the company’s Avandia diabetes drug can cause heart attacks and strokes, people familiar with the accords said.
Roche Holding AG may get the first signs at a cardiology conference this month that the Swiss drugmaker can garner $6.8 billion in sales with a pill to combat heart disease by raising so-called good cholesterol.
GlaxoSmithKline Plc agreed to pay about $60 million in the first settlements of lawsuits alleging the company’s Avandia diabetes drug causes heart attacks and strokes in some users, people familiar with the accords said.
Sanofi-Aventis SA , the French drugmaker that made a takeover approach to Genzyme Corp. two weeks ago, said profit may fall this year after U.S. regulators approved a generic rival to its Lovenox blood thinner.
AstraZeneca Plc named Martin Mackay to lead research and development, hiring a Pfizer Inc. executive for the second time this year as the U.K. drugmaker seeks to replace revenue it’s losing to generic competitors.